Prices of major drugs for treating cancer, diabetes and blood pressure cut by 25%
June 7, 2016
Prices of 56 important medicines used in treatment of cancer, diabetes, bacterial infections and blood pressure have been capped by the government, thereby reducing the cost by an average of nearly 25 per cent.
Drug price regulator National Pharmaceutical Pricing Authority (NPPA), has also increased prices of some of the smaller volume packs of commonly used intravenous fluid such as glucose and sodium chloride injections.
Products of major pharmaceutical firms, including Abbott Healthcare, Cipla, Lupin, Alembic, Alkem Laboratories, Novartis, Biocon, Intas Pharmaceuticals, Hetero Healthcare and erstwhile Ranbaxy (now Sun Pharmaceutical Industries) will be affected by the new price cap announced by NPPA.
“The prices of drugs have been reduced on an average of 25 per cent. In some cases the reduction is 10 to 15 per cent while for others it is up to 45 to 50 per cent also,” NPPA Chairman Bhupendra Singh said.